Advanced search
Publication Cover
Journal of Medical Economics Volume 13, 2010 - Issue 2
Submit an article Journal homepage
1,059
Views
32
CrossRef citations to date
0
Altmetric
Original Article

Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013

Alain Denis Yellow Window Management Consultants, Antwerp, Belgium
,
Lut Mergaert Yellow Window Management Consultants, Antwerp, Belgium
,
Christel Fostier Yellow Window Management Consultants, Antwerp, Belgium
,
Irina Cleemput Belgian Health Care Knowledge Centre, Brussels, Belgium
&
Steven Simoens Research Centre for Pharmaceutical Care and Pharmaco-economics, Katholieke Universiteit Leuven, Leuven, BelgiumCorrespondence[email protected]
Pages 295-301 | Published online: 18 May 2010

References

  • European Commission. Regulation (EC) No 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities 2000; L 18/1
  • European Medicines Agency. Annual Report of the European Medicines Agency 2007. European Medicines Agency, London 2008
  • Denis A, Simoens S, Fostier C, et al. Health technology assessment policy governing orphan diseases and orphan medicines. Belgian Health Care Knowledge Centre, Brussels 2009
  • Rinaldi A. Adopting an orphan. EMBO Rep 2005; 6: 507–510
  • Heemstra HE, de Vrueh RL, van Weely S, et al. Orphan drug development across Europe: bottlenecks and opportunities. Drug Discov Today 2008; 13: 670–676
  • Schlander M, Beck M. Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI. Curr Med Res Opin 2009; 25: 1285–1293
  • Cleemput I, Neyt M, Thiry N, et al. Cost-effectiveness thresholds in health care. Belgian Healthcare Knowledge Centre, Brussels 2008
  • Drummond M, Evans B, LeLorier J, et al. Evidence and values: requirements for public reimbursement of drugs for rare diseases – a case study in oncology. Can J Clin Pharmacol 2009; 16: e273–281
  • McCabe C, Tsuchiya A, Claxton K, et al. Orphan drugs revisited. Q J Med 2006; 99: 341–345
  • RIZIV. Pharmaceutical specialties. RIZIV, Brussels 2010
  • RIZIV. Monitoring of Reimbursement Significant Expenses (MORSE). RIZIV, Brussels 2008
  • Committee for Orphan Medicinal Products. January 2009 plenary meeting: monthly report. European Medicines Agency, London 2009
  • Cook JP, Vernon JA, Manning R. Pharmaceutical risk-sharing agreements. Pharmacoeconomics 2008; 26: 551–556

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.